% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lange:843773,
      author       = {Lange, Catharina and Suppa, Per and Pietrzyk, Uwe and
                      Makowski, Marcus R. and Spies, Lothar and Peters, Oliver and
                      Buchert, Ralph},
      title        = {{P}rediction of {A}lzheimer’s {D}ementia in {P}atients
                      with {A}mnestic {M}ild {C}ognitive {I}mpairment in
                      {C}linical {R}outine: {I}ncremental {V}alue of {B}iomarkers
                      of {N}eurodegeneration and {B}rain {A}myloidosis {A}dded
                      {S}tepwise to {C}ognitive {S}tatus},
      journal      = {Journal of Alzheimer's disease},
      volume       = {61},
      number       = {1},
      issn         = {1875-8908},
      address      = {Amsterdam},
      publisher    = {IOS Press},
      reportid     = {FZJ-2018-01316},
      pages        = {373 - 388},
      year         = {2018},
      abstract     = {The aim of this study was to evaluate the incremental
                      benefit of biomarkers for prediction of Alzheimer’s
                      disease dementia (ADD) in patients with mild cognitive
                      impairment (MCI) when added stepwise in the order of their
                      collection in clinical routine. The model started with
                      cognitive status characterized by the ADAS-13 score.
                      Hippocampus volume (HV), cerebrospinal fluid (CSF)
                      phospho-tau (pTau), and the FDG t-sum score in an AD
                      meta-region-of-interest were compared as neurodegeneration
                      markers. CSF-Aβ1-42 was used as amyloidosis marker. The
                      incremental prognostic benefit from these markers was
                      assessed by stepwise Kaplan-Meier survival analysis in 402
                      ADNI MCI subjects. Predefined cutoffs were used to
                      dichotomize patients as ‘negative’ or ‘positive’ for
                      AD characteristic alteration with respect to each marker.
                      Among the neurodegeneration markers, CSF-pTau provided the
                      best incremental risk stratification when added to ADAS-13.
                      FDG PET outperformed HV only in MCI subjects with relatively
                      preserved cognition. Adding CSF-Aβ provided further risk
                      stratification in pTau-positive subjects, independent of
                      their cognitive status. Stepwise integration of biomarkers
                      allows stepwise refinement of risk estimates for MCI-to-ADD
                      progression. Incremental benefit strongly depends on the
                      patient’s status according to the preceding diagnostic
                      steps. The stepwise Kaplan-Meier curves might be useful to
                      optimize diagnostic workflow in individual patients.},
      cin          = {INM-4 / JARA-BRAIN},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-4-20090406 / $I:(DE-82)080010_20140620$},
      pnm          = {573 - Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000416369700032},
      doi          = {10.3233/JAD-170705},
      url          = {https://juser.fz-juelich.de/record/843773},
}